Serum Amikacin Trough Level Timing
Obtain the serum amikacin trough level before the third dose (predose), which corresponds to approximately one week after initiating therapy.
Monitoring Schedule
The British Thoracic Society guidelines provide clear direction on amikacin therapeutic drug monitoring 1:
Initial Monitoring
- Trough levels: Begin weekly for the first 4 weeks
- First trough measurement: Predose (immediately before the third or fourth dose administration)
- Peak levels: Obtain in the first week of therapy
Timing Rationale
The recommendation to check levels around the third dose (approximately one week into therapy) allows sufficient time for the drug to approach steady-state concentrations while enabling early detection of accumulation, particularly in patients with unrecognized renal impairment. This timing balances the need for therapeutic efficacy against the risk of nephrotoxicity and ototoxicity—both irreversible complications that increase with drug accumulation 1.
Target Concentrations
Trough: <5 mg/L (critical safety threshold)
Peak:
- 25-35 mg/L for daily dosing
- 65-80 mg/L for three-times-weekly dosing 1
The FDA label confirms that peak concentrations above 35 mcg/mL and trough concentrations above 10 mcg/mL should be avoided 2.
Subsequent Monitoring
After the initial week:
- Continue weekly trough levels for 4 weeks
- Reduce to fortnightly once levels are stable 1
- Repeat peak levels only if there is poor clinical response
Critical Safety Considerations
Dose Adjustments Based on Levels
- High trough: Extend dosing interval immediately
- High peak: Reduce dose
- Low peak: Increase dose 1
Renal Function Monitoring
Monitor renal function twice weekly during month 1, then weekly during month 2, then fortnightly thereafter 1. This is essential because aminoglycoside nephrotoxicity is cumulative and may not be immediately apparent.
Ototoxicity Surveillance
Perform baseline audiometry before starting amikacin, then monthly audiometry throughout treatment 1. Ototoxicity is typically irreversible, making prevention through appropriate dosing and monitoring paramount for patient quality of life.
Common Pitfall
The most significant error is delaying trough level measurement beyond the first week. Waiting too long risks accumulation in patients with declining renal function, increasing the likelihood of irreversible ototoxicity and nephrotoxicity. The guideline-recommended approach of checking levels around the third dose (within the first week) provides the optimal window for early intervention 1.